Cohance Lifesciences
Cohance Lifesciences Share Price Chart
Cohance Lifesciences last traded at ₹443.80 (2026-10-13). Over the past month the stock moved -0.1%, three months the stock moved +2.0%, year the stock moved -51.2%. Its closing range over 52 weeks is ₹279.90 – ₹889.95, with the latest close 50.1% below the high.
Closing prices up to 2026-10-13.
About Cohance Lifesciences
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]
Market Position The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Cohance Lifesciences reported sales of ₹422.00 crore (-23.1%) and net profit of ₹-45.00 crore (-197.8%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 422.00 | 1.00 | 0.30 | -45.00 | -0.63 |
| Mar 2026 | 619.00 | 99.00 | 16.00 | 8.00 | 0.51 |
| Dec 2025 | 545.00 | 95.00 | 18.00 | 29.00 | 0.96 |
| Sep 2025 | 556.00 | 121.00 | 22.00 | 66.00 | 1.94 |
| Jun 2025 | 549.00 | 112.00 | 20.00 | 46.00 | 1.28 |
| Mar 2025 | 840.00 | 229.00 | 27.00 | 117.00 | 4.73 |
| Dec 2024 | 676.00 | 237.00 | 35.00 | 153.00 | 6.01 |
| Sep 2024 | 604.00 | 205.00 | 34.00 | 138.00 | 5.44 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +161.5% | +207.3% | +232.0% | +12.5% | -7.9% | -19.4% | -26.3% | -23.1% |
| Operating profit growth | +109.2% | +259.1% | +213.7% | -10.4% | -41.0% | -59.9% | -56.8% | -99.1% |
| Net profit growth | +72.5% | +225.5% | +120.8% | -38.7% | -52.2% | -81.0% | -93.2% | -197.8% |
| EPS growth | +73.8% | +226.6% | +125.2% | -56.8% | -64.3% | -84.0% | -89.2% | -149.2% |
| OPM % | 34.0% | 35.0% | 27.0% | 20.0% | 22.0% | 18.0% | 16.0% | 0.3% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Cohance Lifesciences reported sales of ₹2,269.00 crore (+89.4%) and net profit of ₹150.00 crore (-43.4%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2,269 | 427.00 | 19.00 | 150.00 | 4.68 |
| Mar 2025 | 1,198 | 375.00 | 31.00 | 265.00 | 10.52 |
| Mar 2024 | 1,051 | 406.00 | 39.00 | 300.00 | 11.80 |
| Mar 2023 | 1,340 | 574.00 | 43.00 | 411.00 | 16.16 |
| Mar 2022 | 1,320 | 582.00 | 44.00 | 454.00 | 17.83 |
| Mar 2021 | 1,010 | 443.00 | 44.00 | 362.00 | 14.23 |
| Mar 2020 | 834.00 | 385.00 | 46.00 | 317.00 | 12.45 |
| Mar 2019 | 378.00 | 172.00 | 45.00 | 109.00 | – |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales growth | +120.6% | +21.1% | +30.7% | +1.5% | -21.6% | +14.0% | +89.4% |
| Operating profit growth | +123.8% | +15.1% | +31.4% | -1.4% | -29.3% | -7.6% | +13.9% |
| Net profit growth | +190.8% | +14.2% | +25.4% | -9.5% | -27.0% | -11.7% | -43.4% |
| EPS growth | – | +14.3% | +25.3% | -9.4% | -27.0% | -10.8% | -55.5% |
| OPM % | 46.0% | 44.0% | 44.0% | 43.0% | 39.0% | 31.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Cohance Lifesciences.
Get Free AI Stock Analysis FREE →Latest News
-
Cohance Lifesciences to host investor meets in Mumbai, Hyderabad - scanx.trade
-
Cohance Lifesciences receives four observations from USFDA for Telangana FDF plant
-
Cohance Lifesciences' Telangana units gets Form FDA 483 with observations from US FDA - Business Standard
-
USFDA completes inspection of Cohance Lifesciences' formulations unit - Business Standard
-
Cohance Lifesciences' Telangana units gets Form FDA 483 with observations from US FDA - Business Standard
-
USFDA completes inspection of Cohance Lifesciences' formulations unit - Business Standard
-
Cohance Lifesciences To Invest USD 18 Mn in NJ Bio, Aruka Bio
-
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio - The Economic Times
-
Cohance Lifesciences receives five observations from USFDA for Pashamylaram facility
-
Cohance Surges Nearly 14% to Rs 461.35, Leads Mid-Small Healthcare Rally on Tuesday
Frequently Asked Questions
What is Cohance Lifesciences's current stock price?
Cohance Lifesciences shares were last quoted at ₹443.80 (+0.6% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Cohance Lifesciences?
Cohance Lifesciences has a price-to-earnings (P/E) ratio of 164.78 and a price-to-book (P/B) ratio of 4.54. The industry P/E is 53.33.
What is the 52-week high and low of Cohance Lifesciences?
The 52-week high of Cohance Lifesciences is ₹917.50 and the 52-week low is ₹267.85.
What is the market cap of Cohance Lifesciences?
The market capitalisation of Cohance Lifesciences is about ₹17,526.78 crore.
How did Cohance Lifesciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), Cohance Lifesciences reported sales of ₹422.00 crore (-23.1%) and net profit of ₹-45.00 crore (-197.8%), compared with the same quarter last year.
Is Cohance Lifesciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Cohance Lifesciences has a 3-year ROE of 11.00%, 3-year profit growth of -21.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Cohance Lifesciences?
Promoters hold about 57.49% of Cohance Lifesciences.
Which sector does Cohance Lifesciences belong to?
Cohance Lifesciences belongs to the Pharmaceuticals & Drugs sector.